Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2006-04-03
2010-11-02
Minnifield, N. M (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S184100, C424S190100, C424S236100, C424S237100, C424S239100, C424S241100, C424S243100, C424S246100, C424S247100, C424S257100, C424S422000, C424S423000, C424S430000, C514S008100, C514S002600
Reexamination Certificate
active
07824691
ABSTRACT:
The present composition combines an RNAIII-inhibiting peptide (RIP) with an antimicrobial peptide, such as a cathelicidin, that is capable of binding and neutralizing lipidic and polyanionic components of bacterial cell envelope. In another embodiment, the RIP is combined with an antibiotic, with or without an antimicrobial peptide. The present composition is advantageously used in a method of treatment of bacterial sepsis.
REFERENCES:
patent: 5049322 (1991-09-01), Devissaguet et al.
patent: 6291431 (2001-09-01), Balaban et al.
patent: 6447786 (2002-09-01), Novick et al.
patent: 6689878 (2004-02-01), Balaban et al.
patent: 6706289 (2004-03-01), Lewis et al.
patent: 6747129 (2004-06-01), Balaban et al.
patent: 7067135 (2006-06-01), Balaban
patent: 7323179 (2008-01-01), Balaban
patent: 2002/0102271 (2002-08-01), Balaban et al.
patent: 2003/0050248 (2003-03-01), Wright et al.
patent: 2004/0072748 (2004-04-01), Balaban
patent: 2004/0077534 (2004-04-01), Balaban
patent: 2006/0252691 (2006-11-01), Balaban
patent: 2007/0009566 (2007-01-01), Balaban
patent: 2007/0009567 (2007-01-01), Balaban
patent: 2007/0009569 (2007-01-01), Balaban
patent: 2007/0015685 (2007-01-01), Balaban
patent: 2007/0071768 (2007-03-01), Balaban
patent: 2007/0092575 (2007-04-01), Balaban et al.
patent: 2007/0254006 (2007-11-01), Loose et al.
patent: 2007/0293435 (2007-12-01), Balaban et al.
patent: 2008/0138332 (2008-06-01), Balaban
patent: 2008/0152701 (2008-06-01), Balaban
patent: 2008/0219976 (2008-09-01), Balaban
patent: 2009/0092578 (2009-04-01), Su et al.
patent: 0 395 099 (1990-10-01), None
patent: 1 188 831 (2002-03-01), None
patent: 96/10579 (1996-04-01), None
patent: 97/44349 (1997-11-01), None
patent: 99/32133 (1999-07-01), None
patent: 2005/009396 (2005-02-01), None
patent: WO 2006/107944 (2006-10-01), None
patent: WO 2006/107945 (2006-10-01), None
patent: WO 2006/107946 (2006-10-01), None
patent: WO 2006/122127 (2006-11-01), None
Ghiselli et al, Shock, 2006, 26/3:296-301.
Tsang et al, Infection and Immunity, Sep. 2007, 75/9:4528-4533.
Cirioni et al, J. Infectious Diseases, 2006, 193:180-186.
Simonetti et al, Antimicrobial Agents and Chemotherapy, Jun. 2008, 52/6:2205-2211.
Balaban et al, Clinical Orthopaedics and Related Research, 2005, 437:48-54.
Balaban et al, Antimicrobial Agents and Chemotherapy, Jun. 2007, 51/6:2226-2229.
Cirioni et al, Antimicrobial Agents and Chemotherapy, Dec. 2007, 51/12:4518-4520.
March et al, Current Opinion in Biotechnology, 2004, 15:495-502.
U.S. Appl. No. 11/414,350, filed May 1, 2006, Balaban.
U.S. Appl. No. 11/440,093, filed May 25, 2006, Balaban.
U.S. Appl. No. 11/441,229, filed May 26, 2006, Balaban.
U.S. Appl. No. 11/394,228, filed Mar. 21, 2006, Balaban et al.
U.S. Appl. No. 11/480,825, filed Jul. 6, 2006, Balaban et al.
U.S. Appl. No. 11/395,294, filed Apr. 3, 2006, Balaban.
U.S. Appl. No. 11/430,091, filed May 9, 2006, Balaban et al.
Balaban et al., “Autocrine regulation of toxin synthesis byStaphylococcus aureus.” Proc. Nat'l Acad. Sci. USA 92:1619-1623 (1995).
Balaban et al., “Translation of RNAIII, theStaphylococcus aureus agrregulatory RNA molecule, can be activated by a 3'-end deletion.”FEMS Microbiol. Lett. 133: 155-161 (1995).
Balaban et al., “Autoinducer of virulence as a target for vaccine and therapy againstStaphylococcus aureus.” Science280: 438-440 (1998).
Balaban et al., “Prevention of diseases caused byStaphylococcus aureususing the peptide RIP.”Peptides21: 1301-1311 (2000).
Balaban et al., “Activation and inhibition of theStaphylococcus agrsystem.”Science287: 391a (2000).
Balaban et al., “Regulation ofStaphylococcus aureuspathogenesis via target of RNAIII-activating Protein (TRAP).”J. Biol. Chem. 276: 2658-2667 (2001).
Balaban et al., “Prevention ofStaphylococcus aureusbiofilm on dialysis catheters and adherence to human cells.”Kidney Int'l63: 340-345 (2003).
Balaban et al., “Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistantStaphylococcus epidermidis.” J. Infect. Dis. 187: 625-630 (2003).
Balaban et al., “A chimeric peptide composed of a dermaseptin derivative and an RNA III-inhibiting peptide prevents graft-associated infections by antibiotic-resistant staphylococci.”Antimicrob. Agents Chemother. 48: 2544-2550 (2004).
Benincasa et al., “In vitro and in vivo antimicrobial activity of two alpha-helical cathelicidin peptides and of their synthetic analogs.”Peptides24:1723-1731 (2003).
Cannon, “Antimicrobial peptides. A family of wound healers.”Nature28: 478 (1987).
Cirioni et al., “Prophylactic efficacy of topical temporin A and RNAIII-inhibiting peptide in a subcutaneous rat pouch model of graft infection attributable to staphylococci with intermediate resistance to glycopeptides.”Circulation108: 767-771 (2003).
Costerton et al., “Bacterial biofilms: a common cause of persistent infections.”Science284: 1318-1322 (1999).
De Kimpe et al., “The cell wall components peptidoglycan and lipoteichoic acid fromStaphylococcus aureusact in synergy to cause shock and multiple organ failure.”Proc. Nat'l Acad. Sci. USA 92:10359-10363 (1995).
Dell'Acqua et al., “Suppression of drug-resistant staphylococcal infections by the quorum-sensing inhibitor RNAIII-inhibiting peptide.”J. Infect. Dis. 190: 318-320 (2004).
Domenico et al., “BisEDT and RIP act in synergy to prevent graft infections by resistant staphylococci.”Peptides25: 2047-2053 (2004).
Ganz et al., “Antimicrobial peptides of leukocytes.”Curr. Opin. Hematol. 4: 53-58 (1997).
Ghiselli et al., “RNAIII-inhibiting peptide and/or nisin inhibit experimental vascular graft infection with methicillin-susceptible and methicillin-resistantStaphylococcus epidermidis.” Eur. J. Vasc. Endovasc. Surg. 27: 603-607 (2004).
Giacometti et al., “RNA III inhibiting peptide inhibits in vivo biofilm formation by drug-resistantStaphylococcus aureus.” Antimicrob. Agents Chemother. 47: 1979-1983 (2003).
Giacometti et al., “RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis.”Peptides26: 169-175 (2005).
Giacometti et al., “Administration of protegrin peptide IB-367 to prevent endotoxin induced mortality in bile duct ligated rats.”Gut52: 874-878 (2003).
Giacometti et al., “Cathelicidin peptide sheep myeloid antimicrobial peptide-29 prevents endotoxin-induced mortality in rat models of septic shock.”Am. J. Respir. Crit. Care Med. 169: 187-194 (2004).
Gough et al., “Antiendotoxin activity of cationic peptide antimicrobial agents.”Infect. Immun. 64: 4922-4927 (1996).
Gov et al., “RNAIII inhibiting peptide (RIP), a global inhibitor ofStaphylococcus aureuspathogenesis: structure and function analysis.”Peptides22: 1609-1620 (2001).
Gov et al., “Quorum sensing in Staphylococci is regulated via phosphorylation of three conserved histidine residues.”J. Biot. Chem. 279: 14665-14672 (2004).
Hancock et al., “Cationic peptides: a new source of antibiotics.”Trends Biotechnol. 6: 82-88 (1998).
Hancock et al., “The role of antimicrobial peptides in animal defenses.”Proc. Nat'l Acad. Sci. USA 97: 8856-8861 (2000).
Hancock, “Cationic peptides: effectors in innate immunity and novel antimicrobials.”Lancet Infect. Dis. 1: 156-164 (2001).
Hancock, “Host defence (cationic) peptides: what is their future clinical potential?”Drugs. 57: 469-473 (19999).
Hartman et al., “Quorum sensing: potential means of treating gram-negative infections?”Lancet351: 848-849 (1998).
Hwang et al., “Structure-function relationships of antimicrobial peptides.”Biochem. Cell. Biol. 76: 235-246 (1998).
Ji et al., “Cell density control of Staphylococcus virulence mediated by an octapeptide pheromone.”Proc. Nat'l
Centegen, Inc.
DLA Piper (LLP) US
Minnifield N. M
LandOfFree
Use of RIP in treating staphylococcus aureus infections does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of RIP in treating staphylococcus aureus infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of RIP in treating staphylococcus aureus infections will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4171005